Work

Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer

Year: 2007

Type: article

Study design: Study Protocol

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-07-0717

Authors: Bruce E. Johnson, David Jackman, Pasi A. Jänne

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2160565595

FWCI: 5.21

Cites: 29

Cited by: 43

Related to: 10